Merck KGaA (FRA:MRK) PT Set at €110.00 by JPMorgan Chase & Co.
JPMorgan Chase & Co. set a €110.00 ($123.60) price target on Merck KGaA (FRA:MRK) in a report released on Wednesday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other research firms also recently issued reports on MRK. HSBC set a €101.00 ($113.48) target price on shares of Merck KGaA and gave the company a neutral rating in a research report on Monday, May 18th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research report on Wednesday, July 22nd. Sanford C. Bernstein set a €115.00 ($129.21) target price on shares of Merck KGaA and gave the company a neutral rating in a research report on Monday, June 8th. Kepler Capital Markets set a €122.00 ($137.08) target price on shares of Merck KGaA and gave the company a sell rating in a research report on Wednesday, July 1st. Finally, Warburg Research set a €106.00 ($119.10) target price on shares of Merck KGaA and gave the company a neutral rating in a research report on Thursday, May 14th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €108.64 ($122.07).
Merck KGaA stock opened at €108.05 ($121.40) on Wednesday. The business has a 50 day moving average of €107.71 and a 200-day moving average of €106.94. Merck KGaA has a 1 year low of €76.60 ($86.07) and a 1 year high of €115.00 ($129.21).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: What is the S&P/ASX 200 Index?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.